Skip to main content
      Pearls on EGPA:
      1. GC are mainstay for mild
      dz
      2. Organ threatening/relapsing➡️CYP (RTX alternative)
      3. W/o organ th

      Adela Castro AdelaCastro222

      3 months ago
      Pearls on EGPA: 1. GC are mainstay for mild dz 2. Organ threatening/relapsing➡️CYP (RTX alternative) 3. W/o organ threatening➡️ anti-IL-5/IL-5R. 4. IL5i are less effective for ENT 5. Consider sx for nasal polyps. #EULAR2025 @RheumNow https://t.co/zoJEWxafsN
      EULAR FMF recommendations 2025:
      still emphasis on colchicine adherence to maximal dose
      +/- bDMARDs if needed for control

      David Liew drdavidliew

      3 months ago
      EULAR FMF recommendations 2025: still emphasis on colchicine adherence to maximal dose +/- bDMARDs if needed for control +/- csDMARDs for residual chronic MSK involvement new: consider tapering bDMARD if remission >6mo See the treatment algorithm below⬇️ #EULAR2025 @RheumNow https://t.co/Hy6DOKzfUL
      Key summary slide of research in the use of CD19 CAR T cells in rheumatology indications

      Dinesh Khanna @RheumNow #EULAR

      Antoni Chan MD (Prof) synovialjoints

      3 months ago
      Key summary slide of research in the use of CD19 CAR T cells in rheumatology indications Dinesh Khanna @RheumNow #EULAR2025 https://t.co/CoFHqaE1L1
      Despite the evolution of anti-synthetase antibodies, there’s a clear need for better ways to define the disease.

      Ente

      David Liew drdavidliew

      3 months ago
      Despite the evolution of anti-synthetase antibodies, there’s a clear need for better ways to define the disease. Enter the ACR/EULAR CLASS initiative - classification criteria for anti-synthetase syndrome ⬇️ see the next tweet #EULAR2025 @RheumNow https://t.co/Z3rPOt1vlx
      FMF #Recommendations

      🔺️Start Colchicine in All (& continue for confirmed pts)
      🔺️Single or divided dose, d

      Nelly ZIADE 🍀 Nellziade

      3 months ago
      FMF #Recommendations 🔺️Start Colchicine in All (& continue for confirmed pts) 🔺️Single or divided dose, depend on adherence & tolerance 🔺️Max dose 2 mg children, 3 mg adults 🔺️if failure: add IL1i (6 RCT) (2 for IL6i) 🔺️Add c or bDMARd if MSK #EULAR2025 @RheumNow https://t.co/fPyQrLbb6S
      FMF #Recommendations

      During attack:
      🔺️No use of increasing Colchicine
      🔺️No use for corticosteroids and opioi

      Nelly ZIADE 🍀 Nellziade

      3 months ago
      FMF #Recommendations During attack: 🔺️No use of increasing Colchicine 🔺️No use for corticosteroids and opioid 🔺️Use NSAIDs #EULAR2025 @RheumNow https://t.co/jJjWJra7yr
      EULAR/ACR Classification Criteria for #ASyS, the new acronym of Antisynthetase Syndrome

      🔺️Do not apply if patient

      Nelly ZIADE 🍀 Nellziade

      3 months ago
      EULAR/ACR Classification Criteria for #ASyS, the new acronym of Antisynthetase Syndrome 🔺️Do not apply if patient is positive for other antibodies like SSA #EULAR2025 @RheumNow https://t.co/AD5tTipBtt
      What is the difference between difficult to treat, and treatment-refractory?
      (see these criteria for PsA)

      Treatment ref

      David Liew drdavidliew

      3 months ago
      What is the difference between difficult to treat, and treatment-refractory? (see these criteria for PsA) Treatment refractory means that co-morbidities, psychosocial issues and other factors have been managed adequately, but inflammation keeps on going #EULAR2025 @RheumNow https://t.co/Fzpf0eiCWY
      FMF #Recommendations

      #Colchicine can be fatal

      🔺️Beware of drug interactions
      🔺️Mostly statins in adults
      🔺?

      Nelly ZIADE 🍀 Nellziade

      3 months ago
      FMF #Recommendations #Colchicine can be fatal 🔺️Beware of drug interactions 🔺️Mostly statins in adults 🔺️Macrolides in children #EULAR2025 @RheumNow https://t.co/SYGLpAJXFu
      Joint pain and fatigue are actually the biggest issues for people living with haemochromatosis, but we in rheumatology d

      David Liew drdavidliew

      3 months ago
      Joint pain and fatigue are actually the biggest issues for people living with haemochromatosis, but we in rheumatology don’t have organized care for them. A call to action from Patrick Kiely, to do better by these patients #EULAR2025 @RheumNow https://t.co/h3Zvov642L
      ×